10-Q Filing

Oruka Therapeutics, Inc. CIK: 907654 Q2 2015

Filing Information

Form Type	10-Q
Accession Number	`0001564590-15-007020`
Period End Date	20150630
Filing Date	20150811
Fiscal Year	2015
Fiscal Period	Q2
XBRL Instance	abio-20150630.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 47 Income Statement 37 Cash Flow Statement 51 Stockholders Equity 17

Balance Sheet 47 line items

Line Item	Tag	Value	Unit	Period
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	100.00M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	100.00M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$19.38M	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	63.22M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$16.76M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$15.35M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$44.09M	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	21.15M	shares	Point-in-time
Other current assets	`OtherAssetsCurrent`	$134.00K	USD	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	63.22M	shares	Point-in-time
Other current assets	`OtherAssetsCurrent`	$241.00K	USD	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	21.15M	shares	Point-in-time
Total current assets	`AssetsCurrent`	$15.49M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$44.33M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$34.00K	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$36.00K	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$608.00K	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$754.00K	USD	Point-in-time
Total assets	`Assets`	$45.12M	USD	Point-in-time
Total assets	`Assets`	$16.13M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$714.00K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$795.00K	USD	Point-in-time
Accrued compensation and employee benefits	`EmployeeRelatedLiabilitiesCurrent`	$202.00K	USD	Point-in-time
Accrued compensation and employee benefits	`EmployeeRelatedLiabilitiesCurrent`	$329.00K	USD	Point-in-time
Accrued expenses and other liabilities	`OtherLiabilitiesCurrent`	$264.00K	USD	Point-in-time
Accrued expenses and other liabilities	`OtherLiabilitiesCurrent`	$440.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.39M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.36M	USD	Point-in-time
Deferred rent, net of current portion	`DeferredRentCreditNoncurrent`	$1.00K	USD	Point-in-time
Deferred rent, net of current portion	`DeferredRentCreditNoncurrent`	$3.00K	USD	Point-in-time
Total liabilities	`Liabilities`	$1.39M	USD	Point-in-time
Total liabilities	`Liabilities`	$1.36M	USD	Point-in-time
Commitments and contingencies	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies	`CommitmentsAndContingencies`	-	USD	Point-in-time
Common stock, $0.001 par value; 100 million shares authorized at June 30, 2015 and December 31, 2014; 63,219,990 and 21,150,486 shares issued and outstanding at June 30, 2015 and December 31, 2014, respectively	`CommonStockValue`	$63.00K	USD	Point-in-time
Common stock, $0.001 par value; 100 million shares authorized at June 30, 2015 and December 31, 2014; 63,219,990 and 21,150,486 shares issued and outstanding at June 30, 2015 and December 31, 2014, respectively	`CommonStockValue`	$21.00K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapitalCommonStock`	$133.78M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapitalCommonStock`	$99.34M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-84.62M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-90.08M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$43.76M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$14.74M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$15.58M	USD	Point-in-time
Total liabilities and stockholders equity	`LiabilitiesAndStockholdersEquity`	$45.12M	USD	Point-in-time
Total liabilities and stockholders equity	`LiabilitiesAndStockholdersEquity`	$16.13M	USD	Point-in-time

Income Statement 37 line items

Line Item	Tag	Value	Unit	Period
Research and development	`ResearchAndDevelopmentExpense`	$2.71M	USD	2 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$3.45M	USD	2 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$1.40M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$1.75M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$972.00K	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$2.09M	USD	2 Qtrs
General and administrative	`GeneralAndAdministrativeExpense`	$1.01M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$2.01M	USD	2 Qtrs
Total costs and expenses	`CostsAndExpenses`	$4.80M	USD	2 Qtrs
Total costs and expenses	`CostsAndExpenses`	$2.41M	USD	1 Quarter
Total costs and expenses	`CostsAndExpenses`	$5.46M	USD	2 Qtrs
Total costs and expenses	`CostsAndExpenses`	$2.72M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-4.80M	USD	2 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-2.41M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-2.72M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-5.46M	USD	2 Qtrs
Interest and other income	`InterestAndOtherIncome`	$2.00K	USD	1 Quarter
Interest and other income	`InterestAndOtherIncome`	$3.00K	USD	2 Qtrs
Interest and other income	`InterestAndOtherIncome`	$4.00K	USD	2 Qtrs
Interest and other income	`InterestAndOtherIncome`	$2.00K	USD	1 Quarter
Interest expense	`InterestExpense`	$2.00K	USD	2 Qtrs
Interest expense	`InterestExpense`	$3.00K	USD	2 Qtrs
Interest expense	`InterestExpense`	$1.00K	USD	1 Quarter
Interest expense	`InterestExpense`	$2.00K	USD	1 Quarter
Net loss and comprehensive loss	`NetIncomeLoss`	$-2.72M	USD	1 Quarter
Net loss and comprehensive loss	`NetIncomeLoss`	$-5.46M	USD	2 Qtrs
Net loss and comprehensive loss	`NetIncomeLoss`	$-4.79M	USD	2 Qtrs
Net loss and comprehensive loss	`NetIncomeLoss`	$-9.69M	USD	Annual
Net loss and comprehensive loss	`NetIncomeLoss`	$-2.40M	USD	1 Quarter
Basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.11	USD	1 Quarter
Basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.22	USD	2 Qtrs
Basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.10	USD	1 Quarter
Basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.24	USD	2 Qtrs
Basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	24.43M	shares	2 Qtrs
Basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	21.01M	shares	1 Quarter
Basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	19.90M	shares	2 Qtrs
Basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	27.66M	shares	1 Quarter

Cash Flow Statement 51 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLoss`	$-2.72M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-5.46M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-4.79M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-9.69M	USD	Annual
Net loss	`NetIncomeLoss`	$-2.40M	USD	1 Quarter
Depreciation	`DepreciationAndAmortization`	$9.00K	USD	2 Qtrs
Depreciation	`DepreciationAndAmortization`	$5.00K	USD	2 Qtrs
Amortization of deferred charges	`AmortizationOfDeferredCharges`	$78.00K	USD	2 Qtrs
Share-based compensation	`ShareBasedCompensation`	$305.00K	USD	2 Qtrs
Share-based compensation	`ShareBasedCompensation`	$330.00K	USD	2 Qtrs
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$-86.00K	USD	2 Qtrs
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$-45.00K	USD	2 Qtrs
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$224.00K	USD	2 Qtrs
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$701.00K	USD	2 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$-198.00K	USD	2 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$128.00K	USD	2 Qtrs
Accrued compensation and employee benefits	`IncreaseDecreaseInEmployeeRelatedLiabilities`	$-127.00K	USD	2 Qtrs
Accrued compensation and employee benefits	`IncreaseDecreaseInEmployeeRelatedLiabilities`	$-318.00K	USD	2 Qtrs
Accrued expenses and other liabilities	`IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities`	$24.00K	USD	2 Qtrs
Accrued expenses and other liabilities	`IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities`	$-146.00K	USD	2 Qtrs
Other	`IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet`	$2.00K	USD	2 Qtrs
Other	`IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet`	$-1.00K	USD	2 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivitiesContinuingOperations`	$-5.51M	USD	2 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivitiesContinuingOperations`	$-5.45M	USD	2 Qtrs
Purchase of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$5.00K	USD	2 Qtrs
Purchase of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$7.00K	USD	2 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivitiesContinuingOperations`	$-7.00K	USD	2 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivitiesContinuingOperations`	$-5.00K	USD	2 Qtrs
Proceeds from the issuance of common stock	`ProceedsFromIssuanceOfCommonStock`	$9.04M	USD	2 Qtrs
Proceeds from the issuance of common stock	`ProceedsFromIssuanceOfCommonStock`	$37.00M	USD	2 Qtrs
Common stock offering costs	`PaymentsOfStockIssuanceCosts`	$834.00K	USD	2 Qtrs
Common stock offering costs	`PaymentsOfStockIssuanceCosts`	$2.61M	USD	2 Qtrs
Repayment of principal on vendor finance agreement	`RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths`	$138.00K	USD	2 Qtrs
Repayment of principal on vendor finance agreement	`RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths`	$128.00K	USD	2 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivitiesContinuingOperations`	$8.08M	USD	2 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivitiesContinuingOperations`	$34.25M	USD	2 Qtrs
Net increase in cash and cash equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$28.73M	USD	2 Qtrs
Net increase in cash and cash equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$2.62M	USD	2 Qtrs
Cash and cash equivalents, beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$19.38M	USD	Point-in-time
Cash and cash equivalents, beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$16.76M	USD	Point-in-time
Cash and cash equivalents, beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$15.35M	USD	Point-in-time
Cash and cash equivalents, beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$44.09M	USD	Point-in-time
Cash and cash equivalents, end of period	`CashAndCashEquivalentsAtCarryingValue`	$19.38M	USD	Point-in-time
Cash and cash equivalents, end of period	`CashAndCashEquivalentsAtCarryingValue`	$16.76M	USD	Point-in-time
Cash and cash equivalents, end of period	`CashAndCashEquivalentsAtCarryingValue`	$15.35M	USD	Point-in-time
Cash and cash equivalents, end of period	`CashAndCashEquivalentsAtCarryingValue`	$44.09M	USD	Point-in-time
Interest paid	`InterestPaid`	$2.00K	USD	2 Qtrs
Interest paid	`InterestPaid`	$3.00K	USD	2 Qtrs
Common stock offering costs accrued but not yet paid	`CommonStockOfferingCostsAccruedButNotYetPaid`	$214.00K	USD	2 Qtrs
Vendor finance agreement	`VendorFinanceAgreement`	$51.00K	USD	2 Qtrs
Vendor finance agreement	`VendorFinanceAgreement`	$55.00K	USD	2 Qtrs

Stockholders Equity 17 line items

Line Item	Tag	Value	Unit	Period
Beginning Balance	`StockholdersEquity`	$43.76M	USD	Point-in-time
Beginning Balance	`StockholdersEquity`	$14.74M	USD	Point-in-time
Beginning Balance	`StockholdersEquity`	$15.58M	USD	Point-in-time
Issuance of common stock for cash, net of offering costs	`StockIssuedDuringPeriodValueNewIssues`	$34.17M	USD	2 Qtrs
Issuance of common stock for cash, net of offering costs	`StockIssuedDuringPeriodValueNewIssues`	$7.87M	USD	Annual
Issuance of common stock upon exercise of warrants for cash, value	`IssuanceOfCommonStockUponExerciseOfWarrantsForCashValue`	$338.00K	USD	Annual
Issuance of common stock upon vesting of Restricted Stock Units, value	`StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures`	$-2.00K	USD	Annual
Share-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$647.00K	USD	Annual
Share-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$305.00K	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-2.72M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-5.46M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-4.79M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-9.69M	USD	Annual
Net loss	`NetIncomeLoss`	$-2.40M	USD	1 Quarter
Ending Balance	`StockholdersEquity`	$43.76M	USD	Point-in-time
Ending Balance	`StockholdersEquity`	$14.74M	USD	Point-in-time
Ending Balance	`StockholdersEquity`	$15.58M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.